Brazil benefits from a program, known as the Partnership for Productive Development, that brings together government and the private sector to develop strategic products of interest to the Brazilian health system—including biosimilars of high-cost biologics that account for approximately half of annual drug spending.
In 2010, Brazil’s National Health Surveillance Agency (ANVISA) established criteria for biosimilar approval, forming a comprehensive pathway for these products for the first time. The guidelines, Collegiate Board Resolution 55/2010, provides 2 ways in which a biosimilar can be approved: comparability and individual development.
The comparability demonstration is similar to that described by the World Health Organization. Under Brazil’s comparability pathway, biosimilars require comparative data from preclinical as well as phase 1 and phase 3 clinical studies in relation to the reference product, and the extrapolation of indications is permitted. Robust pharmacovigilance systems, similar to those in place for the reference drug, are required.
Read more about biosimilars in Brazil.
However, the individual development pathway differs significantly from the comparability pathway; individual development requires comparative data only from preclinical trials and phase 3 confirmatory studies, with no requirement to produce comparative data from phase 1 studies. Extrapolation of indications for products developed in this manner are not permitted, and these products may not be treated as interchangeable with their references.
For both types of biosimilar products, explains a newly published paper, Brazil benefits from a program known as the Partnership for Productive Development (PPD), which brings together government and the private sector to develop strategic products of interest to the Brazilian health system—including biosimilars of the high-cost biologics that account for approximately half of annual drug spending.
In an arrangement that the paper calls a “win-win opportunity” for both government and private companies, under a PPD agreement, the master cell bank for a biologic is required by law to be transferred to the government organization participating in the agreement for use in manufacturing, and the biosimilar maker develops a product that will then be purchased directly by the Brazilian Ministry of Health. Thus, the government establishes a supply of a cost-reducing product, and the biosimilar developer ensures robust sales of its product. Biosimilars that are currently part of such agreements include rituximab, adalimumab, and bevacizumab.
The impact of such agreements on Brazil’s healthcare system has the potential to be significant. At the same time, nationalizing production of biosimilars presents an opportunity, say the paper's authors, for the nation to positive impact its trade balance, generate tax revenue, and provide jobs in Brazil.
Reference
Scheinberg MA, Felix PAO, Kos IA, Andrade MA, Azevedo VF. Partnership for productive development of biosimilar products: perspective of access to biological products in the Brazilian market. Einstein (Sao Paulo). 2018;16(3): eRW4175. doi: 10.1590/S1679-45082018RW4175.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.